Skip to main content
Premium Trial:

Request an Annual Quote

A New Kind of Cancer 'Hub'

Premium

Stanford's George Lundberg introduces a new kind of cancer research and information hub in The Scientist this week. Called Cancer Commons, the new platform adds the patient to the publishing equation, in order to advance the way cancer is treated and the way therapies are developed. It blends scientific publishing with social media in "a hub of open-science communities in which physicians, patients, and scientists collaborate on models of cancer subtypes to more accurately predict individual responses to therapy," Lundberg says. The platform's developers are creating molecular disease models for various kinds of cancer, starting with melanoma. They'll match patients with the best individualized treatments based on genomic information and record and disseminate outcomes to the research community, he adds. Subtypes and therapies will be revised based on new information and research. The platform will also include information that's been peer-reviewed, but deemed not ready for prime time in the hopes that it might be helpful to late-stage cancer patients.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.